Pharmaceutical Consulting

Strategic guidance for complex drug development

Nurvya partners with biotech and pharma companies to navigate regulatory pathways, optimize clinical strategy, and bring life-changing therapies to market — faster.

Our Services Start a Conversation
98%
Regulatory submission success rate
120+
Engagements completed
18
Years of combined expertise
FDA EMA Phase I–III Rare Disease Oncology
About Nurvya

Built on deep expertise. Driven by outcomes.

Nurvya was founded by seasoned pharmaceutical scientists and regulatory professionals who saw a gap: sponsors needed nimble, expert guidance without the overhead of a large CRO.

We work as a true extension of your team — embedding ourselves in your programs, challenging assumptions, and delivering rigorous strategy that holds up under FDA and EMA scrutiny.

From early asset evaluation to post-approval lifecycle management, we bring clarity to every stage of drug development.

Scientific rigor
Every recommendation is grounded in evidence, current agency guidance, and precedent from comparable programs.
Speed without shortcuts
We accelerate timelines by front-loading the hard questions — not by cutting corners on quality or compliance.
True partnership
We align our success with yours — working transparently, proactively sharing risks, and celebrating your wins.
What We Do

End-to-end consulting for every stage of development

01
Regulatory Strategy
FDA, EMA, and global health authority interactions. IND/CTA preparation, Breakthrough Therapy, PRIME designation, and pre-submission meeting strategy.
02
Clinical Development Planning
Study design, protocol development, endpoint selection, and adaptive trial frameworks across Phase I–III and beyond.
03
CMC & Manufacturing Advisory
Chemistry, manufacturing, and controls strategy for small molecules, biologics, and advanced therapy medicinal products (ATMPs).
04
Market Access & HEOR
Payer landscape assessment, health economics modeling, and value dossier development to support coverage and reimbursement submissions.
05
Due Diligence & Asset Valuation
Scientific and regulatory due diligence for in-licensing, M&A, and venture investment decisions across therapeutic areas.
06
Lifecycle Management
Post-approval strategies including label expansions, new formulations, combination products, and risk management plan optimization.
Contact

Let's talk about your program

Whether you're evaluating a new asset, preparing a regulatory submission, or navigating a complex development challenge — we're ready to help.

hello@nurvya.com
+1 (215) 555-0194
Philadelphia, PA · Remote engagements welcome

Sending opens your email app with a prepared message addressed to hello@nurvya.com.